Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 5, 2010, Pages 554-560

  Kanazawa, Ippei ^a   Yamaguchi, Toru ^a   Yamamoto, Masahiro ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Insulin; Sulfonylurea; Thiazolidinedione; Type 2 diabetes mellitus; Vertebral fracture

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; VERTEBRA FRACTURE;

AGED; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; SPINAL FRACTURES;

EID: 77956902836     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-010-0160-9     Document Type: Article

References (35)

1. E Barrett-Connor TL Holbrook 1992 Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus JAMA 268 3333 3337 10.1001/jama.268.23.3333 1453525 1:STN:280:DyaK3s%2FosFyhtQ%3D%3D
2. JR Center TV Nguyen D Schneider PN Sambrook JA Eisman 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 878 882 10.1016/S0140-6736(98)09075-8 10093980 1:STN:280:DyaK1M7ptFOlug%3D%3D (Pubitemid 29126875)
3. JA Cauley DE Thompson KC Ensrud JC Scott D Black 2000 Risk of mortality following clinical fractures Osteoporos Int 11 556 561 10.1007/s001980070075 11069188 1:STN:280:DC%2BD3crhtF2gsQ%3D%3D
4. P Vestergaard 2007 Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis Osteoporos Int 18 427 444 10.1007/s00198-006-0253-4 17068657 1:STN:280:DC%2BD2s7jtVCltw%3D%3D (Pubitemid 46354916)
5. LL Lipscombe SA Jamal GL Booth GA Hawker 2007 The risk of hip fractures in older individuals with diabetes: a population-based study Diabetes Care 30 835 841 10.2337/dc06-1851 17392544 (Pubitemid 46556575)
6. ES Strotmeyer JA Cauley AV Schwartz MC Nevitt HE Resnick DC Bauer FA Tylavsky N de Rekeneire TB Harris AB Newman 2005 Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the Health, Aging, and Body Composition Study Arch Intern Med 165 1612 1617 10.1001/archinte.165.14.1612 16043679 (Pubitemid 41124155)
7. M Yamamoto T Yamaguchi M Yamauchi H Kaji T Sugimoto 2009 Diabetic patients have an increased risk of vertebral fractures independent of bone mineral density or diabetic complications J Bone Miner Res 24 702 709 10.1359/jbmr.081207 19049338 1:CAS:528:DC%2BD1MXksF2ksL4%3D
8. AA Ali RS Weinstein SA Stewart AM Parfitt SC Manolagas RI Jilka 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 146 1226 1235 10.1210/en.2004-0735 15591153 1:CAS:528:DC%2BD2MXitlehtro%3D (Pubitemid 40289310)
9. L Tornvig LI Mosekilde J Justesen E Falk M Kassem 2001 Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice Calcif Tissue Int 69 46 50 10.1007/s002230020018 11685433 1:CAS:528:DC%2BD3MXmt1egsr0%3D (Pubitemid 32702265)
10. T Akune S Ohba S Kamekura M Yamaguchi UI Chung N Kubota Y Terauchi Y Harada Y Azuma K Nakamura T Kadowaki H Kawaguchi 2004 PPAR-γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors J Clin Invest 113 846 855 15067317 1:CAS:528:DC%2BD2cXisVagtbw%3D
11. L Pei P Tontonoz 2004 Fat's loss is bone's gain J Clin Invest 113 805 806 15067310 1:CAS:528:DC%2BD2cXisVagtLs%3D
12. MA Soroceau D Miao X-Y Bai H Su D Goltzman AC Karaplis 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J Endocrinol 183 203 216 10.1677/joe.1.05723 1:CAS:528:DC%2BD2cXptlCqsbY%3D (Pubitemid 40124657)
13. SO Rzonca LJ Suva D Gaddy DC Montague B Lecka-Czernik 2004 Bone is a target for the antidiabetic compound rosiglitazone Endocrinology 145 401 406 10.1210/en.2003-0746 14500573 1:CAS:528:DC%2BD3sXhtVWgtL7O (Pubitemid 38094536)
14. YK Loke S Singh CD Furberg 2009 Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis CMAJ (Can Med Assoc J) 180 32 39 10.1503/cmaj.080486
15. DM Thomas DK Hards SD Rogers KW Ng JD Best 1997 Insulin and bone, clinical and scientific view Endocrinol Metab N Am 4 5 17
16. DM Thomas DK Hards SD Rogers KW Ng JD Best 1996 Insulin receptor expression in bone J Bone Miner Res 11 1312 1320 10.1002/jbmr.5650110916 8864906 1:CAS:528:DyaK28Xls1Chtb4%3D
17. P Raskin MRM Stevenson DE Barilla CYC Pak 1978 The hypercalciuria of diabetes mellitus: its amelioration with insulin Clin Endocrinol 9 329 335 10.1111/j.1365-2265.1978.tb02218.x 1:STN:280:DyaE1M%2FmsVajsg%3D%3D (Pubitemid 9037305)
18. JM Gertner WV Tamborlane RL Horst RS Sherwin P Felig M Genel 1980 Mineral metabolism in diabetes mellitus: changes accompanying treatment with portable subcutaneous insulin infusion system J Clin Endocrinol Metab 50 862 866 10.1210/jcem-50-5-862 6246134 1:CAS:528:DyaL3cXktF2qs7c%3D
19. RQ Ivers P Mitchell RG Cumming AJ Peduto 2001 Diabetes and risk of fractures: the Blue Mountains Eye Study Diabetes Care 24 1198 1203 10.2337/diacare.24.7.1198 11423502 1:STN:280:DC%2BD3MzmtF2qtA%3D%3D
20. LJ Melton 3rd CL Leibson SJ Achenbach TM Therneau S Khosla 2008 Fracture risk in type 2 diabetes: update of a population-based study J Bone Miner Res 23 1334 1342 10.1359/jbmr.080323 18348689 (Pubitemid 352040189)
21. P Vestergaard L Rejnmark L Mosekilde 2005 Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk Diabetologia 48 1292 1299 10.1007/s00125-005-1786-3 15909154 1:CAS:528:DC%2BD2MXmtlCkt70%3D (Pubitemid 41186093)
22. WY Fujimoto 1996 Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups Diabetes Med 13 S7 S10 10.1002/(SICI)1096-9136(199601)13:1<7::AID-DIA74>3.0.CO;2-P 1:STN:280:DyaK2s%2FkvFOntg%3D%3D
23. JI Torrens J Skurnick AL Davidow SG Korenman N Santoro M Soto-Greene N Lasser G Weiss Study of Women's Health Across the Nation (SWAN) 2004 Ethnic differences in insulin sensitivity and beta-cell function in premenapausal or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN) Diabetes Care 27 354 361 10.2337/diacare.27.2.354 14747213 (Pubitemid 38174057)
24. HK Genant M Jergas L Palermo M Nevitt RS Valentin D Black SR Cummings 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group J Bone Miner Res 11 984 996 10.1002/jbmr.5650110716 8797120 1:STN:280:DyaK28zptVShtA%3D%3D
25. I Kanazawa T Yamaguchi M Yamamoto M Yamauchi S Yano T Sugimoto 2008 Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men Calcif Tissue Int 83 324 331 10.1007/s00223-008-9178-6 18946627 1:CAS:528:DC%2BD1cXhtlWhsLbN
26. I Kanazawa T Yamaguchi M Yamamoto M Yamauchi S Yano T Sugimoto 2007 Serum insulin-like growth factor-I is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus Osteoporos Int 18 1675 1681 10.1007/s00198-007-0430-0 17632742 1:CAS:528:DC%2BD2sXhtF2ht7nN (Pubitemid 47620319)
27. A Grey M Bolland G Gamble D Wattie A Horne J Davidson IR Reid 2007 The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 92 1305 1310 10.1210/jc.2006-2646 17264176 1:CAS:528:DC%2BD2sXksVSrtr4%3D (Pubitemid 46556402)
28. AV Schwartz DE Sellmeyer E Vittinghoff L Palermo B Lecka-Czernik KR Feingold ES Strotmeyer HE Resnick L Carbone BA Beamer SW Park NE Lane TB Harris SR Cummings 2006 Thiazolidinedione use and bone loss in older diabetic adults J Clin Endocrinol Metab 91 3349 3355 10.1210/jc.2005-2226 16608888 1:CAS:528:DC%2BD28Xpslajt74%3D (Pubitemid 44402103)
29. SE Kahn B Zinman JM Lachin SM Haffner WH Herman RR Holman BG Kravitz D Yu MA Heise RP Aftring G Viberti Diabetes Outcome Progression Trial (ADOPT) Study Group 2008 Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care 31 845 851 10.2337/dc07-2270 18223031 1:CAS:528:DC%2BD1cXmsFGrt7o%3D
30. Schwartz AV (2008) TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008:1-6
31. Ma P, Gu B, Ma J, E L, Wu X, Gao J, Liu H (2009) Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway. Metabolism. doi: 10.1016/j.metabol.2009.08.003
32. WH Daughaday LS Phillips MC Mueller 1976 The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver Endocrinology 98 1214 1219 10.1210/endo-98-5-1214 1261514 1:CAS:528: DyaE28Xkt1yqsrc%3D
33. CD Scott RC Baxter 1986 Production of insulin-like growth factor I and its binding protein in rat hepatocytes cultured from diabetic and insulin-treated diabetic rats Endocrinology 119 2346 2352 10.1210/endo-119-5- 2346 2945714 1:CAS:528:DyaL28Xmt1ert7Y%3D
34. AM Cortizo C Sedlinsky AD McCarthy A Blanco L Schurman 2006 Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture Eur J Phamacol 536 38 46 10.1016/j.ejphar.2006.02.030 1:CAS:528:DC%2BD28Xjs1ajsL8%3D
35. I Kanazawa T Yamaguchi S Yano M Yamauchi T Sugimoto 2008 Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression Biochem Biophys Res Commun 375 414 419 10.1016/j.bbrc.2008.08.034 18721796 1:CAS:528: DC%2BD1cXhtFaqs7nE